A Review Of IMB-808
From the multiday, several-dose arm, baseline microbiota was comparable concerning subjects that gained ibezapolstat in contrast with vancomycin. At Day 10 of dosing, differential abundance Assessment and β-diversity shown a definite difference between the microbiome in subjects given vancomycin as opposed with either dose of ibezapolstat (During